AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38901942 — intervention group
Group type: EXPERIMENTAL
Intervention: CRs' number of comorbidities
Number of subjects: 120
Study 38901942 — intervention group
Group type: EXPERIMENTAL
Intervention: CRs' P-hs-CRP levels
Number of subjects: 120
Study 38901942 — intervention group
Group type: EXPERIMENTAL
Intervention: CRs' hand grip strength
Number of subjects: 120
Study 38901942 — intervention group
Group type: EXPERIMENTAL
Intervention: FCs' MNA scores
Number of subjects: 120
Study 38901946 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime infusions of HPN
Number of subjects: 9
Study 38901946 — intervention group
Group type: COMPARATOR
Intervention: Overnight infusions of HPN
Number of subjects: 9
Study 38901960 — intervention group
Group type: EXPERIMENTAL
Intervention: ILM peeling
Number of subjects: 213
Study 38901960 — intervention group
Group type: COMPARATOR
Intervention: No ILM peeling
Number of subjects: 213
Study 38902005 — intervention group
Group type: EXPERIMENTAL
Intervention: LEV 20 or 40 mg/kg bolus followed by 5 or 10 mg/kg maintenance dose daily (NEOLEV1)
Number of subjects: 49
Study 38902005 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/kg intravenous LEV load, followed by 10 mg/kg doses 8 hourly (NEOLEV2)
Number of subjects: 49
Study 38902005 — intervention group
Group type: EXPERIMENTAL
Intervention: Further 20 mg/kg intravenous load if seizures persisted (NEOLEV2)
Number of subjects: 49
Study 38902005 — intervention group
Group type: COMPARATOR
Intervention: PHB if seizures persisted after LEV (NEOLEV2)
Number of subjects: 49
Study 38902383 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day oseltamivir prophylaxis
Number of subjects: 59
Study 38902383 — intervention group
Group type: COMPARATOR
Intervention: 7-day oseltamivir prophylaxis
Number of subjects: 59
Study 38902464 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurements of waist circumference (WC) at three distinct locations along the abdomen
Number of subjects: 139
Study 38902464 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic (SBP) and diastolic blood pressure (DBP) measurements
Number of subjects: 139
Study 38902464 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional metabolic syndrome (MetS) risk factors
Number of subjects: 139
Study 38902487 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention for patient-partner dyads over 12 weeks
Number of subjects: 23
Study 38902571 — intervention group
Group type: EXPERIMENTAL
Intervention: ALZ-801 265 mg tablet taken twice daily (after 2 weeks once daily)
Number of subjects: 84
Study 38902572 — intervention group
Group type: EXPERIMENTAL
Intervention: ALZ-801 265 mg two times daily (BID)
Number of subjects: 83
Study 38902616 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital physical activity intervention with social support features
Number of subjects: 181
Study 38902616 — intervention group
Group type: COMPARATOR
Intervention: Tablet-based educational control
Number of subjects: 181
Study 38902652 — intervention group
Group type: EXPERIMENTAL
Intervention: IMCY-0098
Number of subjects: 0
Study 38902652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38902668 — intervention group
Group type: EXPERIMENTAL
Intervention: CASC score
Number of subjects: 796
Study 38902668 — intervention group
Group type: COMPARATOR
Intervention: qSOFA score
Number of subjects: 796
Study 38902668 — intervention group
Group type: COMPARATOR
Intervention: NEWS-2 score
Number of subjects: 796
Study 38902691 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone dexborneol (37.5 mg/12 hours, IV)
Number of subjects: 85
Study 38902691 — intervention group
Group type: COMPARATOR
Intervention: Control (no edaravone dexborneol treatment)
Number of subjects: 85
Study 38902731 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control strategy (target BP < 130/80 mmHg)
Number of subjects: 1000
Study 38902731 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1000
Study 38902731 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control strategy
Number of subjects: 1000
Study 38902742 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceval PLUS sutureless valve
Number of subjects: 328
Study 38902747 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and clopidogrel administration
Number of subjects: 988
Study 38902790 — intervention group
Group type: EXPERIMENTAL
Intervention: Male Wolbachia-infected Aedes aegypti deployments
Number of subjects: 0
Study 38902790 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 0
Study 38902794 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 27
Study 38902794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 38902811 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary isocapnic hyperpnoea (VIH) recovery protocol performed 20 min after exercise
Number of subjects: 39
Study 38902811 — intervention group
Group type: COMPARATOR
Intervention: Passive recovery only
Number of subjects: 39
Study 38902836 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrence-focused surveillance including clinical evaluation, serum cancer antigen (CA) 19-9 testing, and contrast-enhanced CT of chest and abdomen every three months for the first 2 years after surgery.
Number of subjects: 0
Study 38902836 — intervention group
Group type: COMPARATOR
Intervention: Non-standardized clinical follow-up consisting of clinical follow-up with imaging and serum tumor marker testing only in case of onset of symptoms, according to local practice.
Number of subjects: 0
Study 38902840 — intervention group
Group type: EXPERIMENTAL
Intervention: Low anterior resection syndrome score (LARS) assessment after colon resection
Number of subjects: 1221
Study 38902840 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of specific bowel symptoms and patient-reported distress
Number of subjects: 1221
Study 38902840 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of loose stools occurrence after right-sided resection
Number of subjects: 1221
Study 38902840 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis of incontinence and loose stools with distress
Number of subjects: 1221
Study 38902846 — intervention group
Group type: EXPERIMENTAL
Intervention: InterCARE care model integrating HIV and hypertension care through provider training, adapted electronic health record, and treatment partners (peer support)
Number of subjects: 290
Study 38902846 — intervention group
Group type: EXPERIMENTAL
Intervention: InterCARE care model
Number of subjects: 290
Study 38902846 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of hypertension services into HIV clinics
Number of subjects: 290
Study 38902860 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of mRNA-1273 (100 μg)
Number of subjects: 100
Study 38902860 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose of mRNA-1273 (2×100 μg)
Number of subjects: 100
Study 38902860 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of Ad26.COV2.S (adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein)
Number of subjects: 100
Study 38902860 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of mycophenolate mofetil/mycophenolic acid after vaccination
Number of subjects: 100
Study 38902860 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of mycophenolate mofetil/mycophenolic acid after vaccination
Number of subjects: 100
Study 38902860 — intervention group
Group type: COMPARATOR
Intervention: 2 primary mRNA-1273 vaccinations (reference group)
Number of subjects: 100
Study 38902928 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg yohimbine and 10 mg hydrocortisone
Number of subjects: 165
Study 38902928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 38902928 — intervention group
Group type: COMPARATOR
Intervention: 10 mg yohimbine
Number of subjects: 165
Study 38902928 — intervention group
Group type: COMPARATOR
Intervention: 10 mg hydrocortisone
Number of subjects: 165
Study 38902952 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy received locally
Number of subjects: 0
Study 38902952 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy received locally
Number of subjects: 0
Study 38902994 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel (150 mg/m2 in D1), oxaliplatin (85 mg/m2 in D1), S-1/leucovorin (35 mg/m2 and 30 mg bid from D1 to D7)
Number of subjects: 19
Study 38903022 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 0
Study 38903173 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent taVNS
Number of subjects: 150
Study 38903173 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential taVNS
Number of subjects: 150
Study 38903173 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 150
Study 38903416 — intervention group
Group type: EXPERIMENTAL
Intervention: VR treatment (3D with binaural beats)
Number of subjects: 21
Study 38903416 — intervention group
Group type: COMPARATOR
Intervention: Control condition (2D with no binaural beats)
Number of subjects: 21
Study 38903523 — intervention group
Group type: EXPERIMENTAL
Intervention: LVRNA012 mRNA vaccine (100ug)
Number of subjects: 2615
Study 38903523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2615
Study 38903809 — intervention group
Group type: EXPERIMENTAL
Intervention: REACHing Equity curriculum delivered virtually in three facilitated, interactive sessions over 7-9 weeks.
Number of subjects: 37
Study 38903809 — intervention group
Group type: EXPERIMENTAL
Intervention: REACHing Equity curriculum
Number of subjects: 37
Study 38904119 — intervention group
Group type: EXPERIMENTAL
Intervention: rESWT
Number of subjects: 200
Study 38904119 — intervention group
Group type: EXPERIMENTAL
Intervention: sham-rESWT
Number of subjects: 200
Study 38904119 — intervention group
Group type: EXPERIMENTAL
Intervention: exercise
Number of subjects: 200
Study 38904119 — intervention group
Group type: COMPARATOR
Intervention: advice plus customised foot orthoses
Number of subjects: 200
Study 38904126 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation behavioural support sessions based on the 5As algorithm and a 6-week supply of nicotine replacement therapy
Number of subjects: 100
Study 38904126 — intervention group
Group type: COMPARATOR
Intervention: Active referral to the Maltese National Health Service's one-to-one smoking cessation support service based on motivational interviewing
Number of subjects: 100
Study 38904129 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-meal tolerance tests (MMTTs) at baseline (n=169) and at 1-year follow-up (n=104)
Number of subjects: 611
Study 38904129 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting residual C-peptide secretion
Number of subjects: 611
Study 38904129 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall C-peptide levels
Number of subjects: 611
Study 38904129 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulated residual C-peptide
Number of subjects: 611
Study 38904136 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth remote patient monitoring (RPM)-based care handoff model
Number of subjects: 0
Study 38904139 — intervention group
Group type: EXPERIMENTAL
Intervention: A-DIVA Scale alone
Number of subjects: 794
Study 38904139 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm for catheter placement
Number of subjects: 794
Study 38904165 — intervention group
Group type: EXPERIMENTAL
Intervention: E4/DRSP (estetrol 15 mg)
Number of subjects: 1553
Study 38904223 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramide-16 (Cer-16)
Number of subjects: 2688
Study 38904223 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramide-20 (Cer-20)
Number of subjects: 2688
Study 38904223 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramide-22 (Cer-22)
Number of subjects: 2688
Study 38904223 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramide-24 (Cer-24)
Number of subjects: 2688
Study 38904223 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphingomyelin-16 (SM-16)
Number of subjects: 2688
Study 38904223 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphingomyelin-20 (SM-20)
Number of subjects: 2688
Study 38904223 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphingomyelin-22 (SM-22)
Number of subjects: 2688
Study 38904223 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphingomyelin-24 (SM-24)
Number of subjects: 2688
Study 38904251 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of serum levels of 4123 unique proteins using a modified aptamer proteomic assay.
Number of subjects: 1117
Study 38904251 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline proteins including B2M, TIMP1, SERPINA4, and SVEP1.
Number of subjects: 1117
Study 38904251 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteomic risk score derived in patients with HFpEF.
Number of subjects: 1117
Study 38904251 — intervention group
Group type: COMPARATOR
Intervention: Comparison with published analyses in 2515 patients with heart failure with reduced ejection fraction from PARADIGM-HF and ATMOSPHERE trials.
Number of subjects: 1117
Study 38904277 — intervention group
Group type: EXPERIMENTAL
Intervention: Brigatinib
Number of subjects: 40
Study 38904646 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP <125 pg/mL
Number of subjects: 3480
Study 38904646 — intervention group
Group type: COMPARATOR
Intervention: NT-proBNP ≥125 pg/mL
Number of subjects: 3480
Study 38904657 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity measured using accelerometry data from the MotionWatch 8
Number of subjects: 204
Study 38904657 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective reports of activities of daily living and other types of physical activity
Number of subjects: 204
Study 38904749 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 131
Study 38904749 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 131
Study 38904749 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg and 2 mg
Number of subjects: 131
Study 38904892 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG)
Number of subjects: 230
Study 38904892 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG) with concomitant G-CSF
Number of subjects: 230
Study 38904899 — intervention group
Group type: EXPERIMENTAL
Intervention: Amberen (dietary supplement)
Number of subjects: 106
Study 38904899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 38904908 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity (BMI ≥ 30 kg/m²) in CAN present group
Number of subjects: 7789
Study 38904908 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity (BMI ≥ 30 kg/m²) in CAN absent group
Number of subjects: 7789
Study 38904908 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing BMI in CAN present group
Number of subjects: 7789
Study 38904908 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing BMI in CAN absent group
Number of subjects: 7789
Study 38904918 — intervention group
Group type: EXPERIMENTAL
Intervention: EVE + EXE (10 mg/day + 25 mg/day)
Number of subjects: 159
Study 38904918 — intervention group
Group type: COMPARATOR
Intervention: PBO + EXE (placebo + 25 mg/day)
Number of subjects: 159
Study 38905143 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P47 via auto-injector (AI)
Number of subjects: 314
Study 38905143 — intervention group
Group type: COMPARATOR
Intervention: CT-P47 via pre-filled syringe (PFS)
Number of subjects: 314
Study 38905148 — intervention group
Group type: EXPERIMENTAL
Intervention: PIEB settings (PIEBnb = 29.4 minutes, PIEBi = 59.8 minutes, PIEBv = 6.2 mL)
Number of subjects: 69
Study 38905148 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA (volume 6 mL every 10 minutes)
Number of subjects: 69
Study 38905174 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple exercise program
Number of subjects: 39
Study 38905174 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive exercise program
Number of subjects: 39
Study 38905174 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 39
Study 38905212 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for ADHD-I (CADDI)
Number of subjects: 14
Study 38905476 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple-based care and treatment intervention
Number of subjects: 1080
Study 38905476 — intervention group
Group type: COMPARATOR
Intervention: Standard of care services
Number of subjects: 1080
Study 38905520 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic Partial Meniscectomy (APM)
Number of subjects: 146
Study 38905520 — intervention group
Group type: COMPARATOR
Intervention: Placebo Surgery
Number of subjects: 146
Study 38905580 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical capsaicin (2 g of capsaicin ointment 0.075%) applied four times a day for 5 days
Number of subjects: 160
Study 38905580 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching ointment)
Number of subjects: 160
Study 38905580 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical capsaicin
Number of subjects: 160
Study 38905580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 38905632 — intervention group
Group type: COMPARATOR
Intervention: Original (unflavored) on! nicotine pouch product
Number of subjects: 400
Study 38905632 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete flavor profile (Berry, Cinnamon, Citrus, Coffee, Mint, Original, Wintergreen) of on! nicotine pouch products
Number of subjects: 400
Study 38905635 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-75276617 (bleximenib)
Number of subjects: 0
Study 38905928 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversal/replacement agent administration during hospitalization (specific agents not detailed).
Number of subjects: 4000
Study 38905928 — intervention group
Group type: COMPARATOR
Intervention: Historic cohort data collection from hospitalization to discharge for patients admitted for major bleeds during FXai use.
Number of subjects: 4000
Study 38905959 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive education programme (e-learning and a two-day course)
Number of subjects: 368
Study 38906161 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus chemotherapy
Number of subjects: 755
Study 38906161 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 755
Study 38906178 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed casein
Number of subjects: 2159
Study 38906178 — intervention group
Group type: COMPARATOR
Intervention: Regular cow milk formula
Number of subjects: 2159
Study 38906178 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow milk antibody concentrations in cord blood
Number of subjects: 2159
Study 38906178 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow milk antibody concentrations longitudinally from birth to 3 years
Number of subjects: 2159
Study 38906178 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent liquid milk consumption after infancy
Number of subjects: 2159
Study 38906210 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix combination therapy (relugolix CT; 40 mg relugolix, 1 mg estradiol, and 0.5 mg norethisterone acetate)
Number of subjects: 277
Study 38906210 — intervention group
Group type: COMPARATOR
Intervention: Delayed relugolix CT
Number of subjects: 277
Study 38906210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 277
Study 38906425 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialty palliative care
Number of subjects: 23
Study 38906440 — intervention group
Group type: EXPERIMENTAL
Intervention: Random forest advanced fibrosis model
Number of subjects: 1198
Study 38906440 — intervention group
Group type: EXPERIMENTAL
Intervention: Random forest cirrhosis model
Number of subjects: 1198
Study 38906453 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted open exposure of palatally impacted canines using a surgical template
Number of subjects: 100
Study 38906453 — intervention group
Group type: COMPARATOR
Intervention: Control group (freehand method)
Number of subjects: 100
Study 38906462 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine particulate matter (PM2.5)
Number of subjects: 5746
Study 38906462 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalable particulate matter (PM10)
Number of subjects: 5746
Study 38906462 — intervention group
Group type: COMPARATOR
Intervention: Nitrogen dioxide (NO2)
Number of subjects: 5746
Study 38906462 — intervention group
Group type: COMPARATOR
Intervention: Sulfur dioxide (SO2)
Number of subjects: 5746
Study 38906462 — intervention group
Group type: COMPARATOR
Intervention: Carbon monoxide (CO)
Number of subjects: 5746
Study 38906462 — intervention group
Group type: COMPARATOR
Intervention: Ozone (O3)
Number of subjects: 5746
Study 38906611 — intervention group
Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 1178
Study 38906611 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-tailored feedback
Number of subjects: 1178
Study 38906611 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored feedback
Number of subjects: 1178
Study 38906614 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-and-pramlintide closed-loop system with simple meal announcements
Number of subjects: 30
Study 38906614 — intervention group
Group type: COMPARATOR
Intervention: Insulin-and-placebo system with carbohydrate counting
Number of subjects: 30
Study 38906707 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 100U
Number of subjects: 55
Study 38906707 — intervention group
Group type: COMPARATOR
Intervention: OnabotulinumtoxinA 25U
Number of subjects: 55
Study 38906707 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 50U
Number of subjects: 55
Study 38906793 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis (LMWH 14%, UFH 8%, SCDs 43%)
Number of subjects: 862
Study 38906793 — intervention group
Group type: COMPARATOR
Intervention: No thromboprophylaxis (21% contraindicated due to thrombocytopenia, 14% lacked documentation)
Number of subjects: 862
Study 38906793 — intervention group
Group type: EXPERIMENTAL
Intervention: SOFA score on the first ICU day
Number of subjects: 862
Study 38906970 — intervention group
Group type: EXPERIMENTAL
Intervention: QL1209
Number of subjects: 585
Study 38906970 — intervention group
Group type: COMPARATOR
Intervention: Pertuzumab
Number of subjects: 585